Covered recipient · General Payments record
LARA SHIRIKJIAN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$137,308.00
148 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $77,961.50 | 56 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,500.83 | 11 |
| Travel and Lodging | $25,570.15 | 38 |
| Food and Beverage | $2,275.52 | 43 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Axsome Therapeutics, Inc. | $66,980.48 | 78 |
| Boehringer Ingelheim International GmbH | $28,310.56 | 7 |
| Janssen Pharmaceuticals, Inc | $26,324.68 | 42 |
| E.R. Squibb & Sons, L.L.C. | $14,726.46 | 18 |
| Janssen Scientific Affairs, LLC | $965.82 | 3 |
Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LARA SHIRIKJIAN
NPI 1609193978 · CMS profile ID 2786475
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
TORRANCE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1609193978?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LARA SHIRIKJIAN, NPI 1609193978, CMS profile ID 2786475. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609193978?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). LARA SHIRIKJIAN, NPI 1609193978, CMS profile ID 2786475. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609193978?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- LARA SHIRIKJIAN, NPI 1609193978, CMS profile ID 2786475, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1609193978?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
148 matching records · $137,308.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–148 of 148.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | $276.65 | 06/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297742 | CMS |
| Janssen Scientific Affairs, LLC | $21.60 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078846053 | CMS |
| Axsome Therapeutics, Inc. | $32.93 | 05/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297628 | CMS |
| Janssen Scientific Affairs, LLC | $6.72 | 05/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078846071 | CMS |
| Axsome Therapeutics, Inc. | $170.18 | 05/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297630 | CMS |
| Axsome Therapeutics, Inc. | $23.90 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297632 | CMS |
| Axsome Therapeutics, Inc. | $125.00 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297634 | CMS |
| Axsome Therapeutics, Inc. | $3,250.00 | 05/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297636 | CMS |
| Axsome Therapeutics, Inc. | $7.50 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297638 | CMS |
| Axsome Therapeutics, Inc. | $13.40 | 04/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297620 | CMS |
| Axsome Therapeutics, Inc. | $123.41 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297622 | CMS |
| Axsome Therapeutics, Inc. | $5.00 | 04/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297624 | CMS |
| Axsome Therapeutics, Inc. | $2,250.00 | 04/30/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297626 | CMS |
| Axsome Therapeutics, Inc. | $1,000.00 | 04/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297618 | CMS |
| Janssen Pharmaceuticals, Inc | $4,800.00 | 03/15/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943558 | CMS |
| Axsome Therapeutics, Inc. | $75.00 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297588 | CMS |
| Axsome Therapeutics, Inc. | $10.17 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297590 | CMS |
| Axsome Therapeutics, Inc. | $8,500.00 | 03/09/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297592 | CMS |
| Axsome Therapeutics, Inc. | $35.00 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297594 | CMS |
| Axsome Therapeutics, Inc. | $35.00 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297596 | CMS |
| Axsome Therapeutics, Inc. | $78.29 | 03/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297598 | CMS |
| Axsome Therapeutics, Inc. | $140.00 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297600 | CMS |
| Axsome Therapeutics, Inc. | $35.00 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297602 | CMS |
| Axsome Therapeutics, Inc. | $21.14 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297604 | CMS |
| Axsome Therapeutics, Inc. | $25.02 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297606 | CMS |
| Axsome Therapeutics, Inc. | $253.49 | 03/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297608 | CMS |
| Axsome Therapeutics, Inc. | $11.39 | 03/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297610 | CMS |
| Axsome Therapeutics, Inc. | $35.00 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297612 | CMS |
| Axsome Therapeutics, Inc. | $21.30 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297614 | CMS |
| Axsome Therapeutics, Inc. | $318.19 | 03/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297616 | CMS |
| Janssen Pharmaceuticals, Inc | $19.20 | 02/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943132 | CMS |
| Janssen Pharmaceuticals, Inc | $54.51 | 02/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943248 | CMS |
| Janssen Pharmaceuticals, Inc | $18.18 | 02/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943392 | CMS |
| Janssen Pharmaceuticals, Inc | $36.37 | 02/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943480 | CMS |
| Janssen Pharmaceuticals, Inc | $106.30 | 02/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943514 | CMS |
| Janssen Pharmaceuticals, Inc | $13.52 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943142 | CMS |
| Janssen Pharmaceuticals, Inc | $16.22 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943190 | CMS |
| Janssen Pharmaceuticals, Inc | $11.27 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943196 | CMS |
| Janssen Pharmaceuticals, Inc | $15.00 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943298 | CMS |
| Janssen Pharmaceuticals, Inc | $94.00 | 02/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943362 | CMS |
| Janssen Pharmaceuticals, Inc | $66.40 | 02/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943436 | CMS |
| Janssen Pharmaceuticals, Inc | $29.37 | 02/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943458 | CMS |
| Janssen Pharmaceuticals, Inc | $386.32 | 02/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943590 | CMS |
| Janssen Pharmaceuticals, Inc | $347.36 | 02/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943674 | CMS |
| Janssen Pharmaceuticals, Inc | $33.06 | 02/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943690 | CMS |
| Janssen Pharmaceuticals, Inc | $124.80 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077943734 | CMS |
| Axsome Therapeutics, Inc. | $1,000.00 | 02/21/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297642 | CMS |
| Axsome Therapeutics, Inc. | $1,000.00 | 02/14/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148297640 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,900.00 | 1 |
| PY2025 | Principal investigator | $2,553,443.17 | 319 |
| PY2024 | Principal investigator | $2,197,606.02 | 209 |
| PY2023 | Recipient | $1,034.25 | 14 |
| PY2023 | Principal investigator | $2,225,578.94 | 342 |
| PY2022 | Principal investigator | $362,905.63 | 75 |
| PY2021 | Principal investigator | $827,522.86 | 139 |
| PY2020 | Principal investigator | $2,065,027.22 | 147 |
| PY2019 | Recipient | $1,510.20 | 7 |
| PY2019 | Principal investigator | $1,833,461.30 | 117 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
320 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 12/11/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049201 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 12/11/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049203 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,500.00 | 12/11/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049205 |
| Principal investigator 1 | ABBVIE INC. | $31,807.02 | 12/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RES | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202529938 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 12/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242368485 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 12/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242368487 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 12/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242368489 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 12/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242368491 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 12/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242368493 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 12/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242368495 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 12/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242368497 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $101.00 | 12/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242368499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737332 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737334 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737336 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737338 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737340 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,140.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737342 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737344 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737346 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737348 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737350 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737352 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737354 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737356 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737358 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737360 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737362 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737364 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737366 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737368 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737370 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737372 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737374 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737376 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737378 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737380 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737382 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737384 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737386 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737388 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737390 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737392 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737394 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737396 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737398 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737400 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737402 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $15,200.00 | 11/24/2025 | Non-covered Recipient Entity Collaborative Neuroscience Network, Llc | A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder | No dispute reported | 06/30/2026 | 1235997934 |
| Principal investigator 1 | ABBVIE INC. | $38,433.19 | 11/17/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RES | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202524483 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $562.93 | 11/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049146 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $168.88 | 11/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049148 |
| Principal investigator 1 | ABBVIE INC. | $1,250.00 | 10/21/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RES | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202517703 |
| Principal investigator 1 | ABBVIE INC. | $1,725.00 | 10/20/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RES | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202517455 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737294 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737296 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737298 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737300 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737302 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737304 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737306 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737308 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737310 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737312 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737314 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737316 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737318 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737320 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737322 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737324 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737326 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737328 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737330 |
| Recipient | ABBVIE INC. | $3,900.00 | 09/26/2025 | Covered Recipient Physician | Major Depressive Disorder | No dispute reported | 06/30/2026 | 1202401337 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,626.81 | 09/24/2025 | Non-covered Recipient Entity Collaborative Neuroscience Network, Llc | A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder | No dispute reported | 06/30/2026 | 1235997932 |
| Principal investigator 1 | ABBVIE INC. | $14,472.90 | 09/19/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RES | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202511698 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 09/12/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RES | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202510888 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,591.35 | 09/12/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049142 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13,260.00 | 09/12/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049144 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 09/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242358586 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 09/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242358588 |
| Principal investigator 1 | ABBVIE INC. | $10,545.00 | 09/03/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RES | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202508422 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $670.70 | 08/26/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049138 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,551.00 | 08/26/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737272 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737274 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737276 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737278 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,212.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737280 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737282 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737284 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737286 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737288 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $325.00 | 08/22/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737292 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,200.00 | 08/20/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242357648 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,514.00 | 08/20/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242357650 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,529.00 | 08/20/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242357656 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,640.25 | 08/14/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049132 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,200.00 | 08/14/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049134 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,560.00 | 08/14/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049136 |
| Principal investigator 1 | ABBVIE INC. | $737.50 | 08/08/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202504149 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,738.10 | 08/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049126 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,500.00 | 08/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049128 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,950.00 | 08/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049130 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,516.20 | 07/31/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049124 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $26,001.79 | 07/30/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049195 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 07/28/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737262 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 07/28/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737264 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 07/28/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737266 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 07/28/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737268 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 07/28/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737270 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,996.74 | 07/28/2025 | Non-covered Recipient Entity Collaborative Neuroscience Network, Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | No dispute reported | 06/30/2026 | 1235997930 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,750.00 | 07/28/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242355504 |
| Principal investigator 1 | ABBVIE INC. | $3,215.60 | 07/24/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder | No dispute reported | 06/30/2026 | 1202499724 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $12,744.25 | 07/22/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049116 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,880.07 | 07/22/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049118 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $104.00 | 07/22/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049120 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $176.00 | 07/22/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049122 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,150.00 | 07/22/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049199 |
| Principal investigator 1 | ABBVIE INC. | $420.83 | 07/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202498952 |
| Principal investigator 1 | ABBVIE INC. | $9,458.00 | 07/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | No dispute reported | 06/30/2026 | 1202498954 |
| Principal investigator 1 | ABBVIE INC. | $21,186.34 | 07/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202498956 |
| Principal investigator 1 | ABBVIE INC. | $208,754.66 | 07/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | No dispute reported | 06/30/2026 | 1202498958 |
| Principal investigator 1 | ABBVIE INC. | $12,189.00 | 07/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | No dispute reported | 06/30/2026 | 1202498960 |
| Principal investigator 1 | ABBVIE INC. | $1,275.00 | 07/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | No dispute reported | 06/30/2026 | 1202498962 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $112,210.40 | 07/18/2025 | Non-covered Recipient Entity Collaborative Neuroscience Network, Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | No dispute reported | 06/30/2026 | 1235997936 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,000.00 | 07/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242353791 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,609.75 | 07/17/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049114 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,747.05 | 07/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049112 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $703.95 | 07/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049106 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $455.00 | 07/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049108 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $215.00 | 07/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049110 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,000.00 | 07/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049189 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 07/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049191 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 07/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049193 |
| Principal investigator 1 | ABBVIE INC. | $1,656.24 | 07/01/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202493867 |
| Principal investigator 1 | ABBVIE INC. | $4,208.29 | 07/01/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202493869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $679.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737246 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737250 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,985.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737254 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737256 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 06/25/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737260 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,017.30 | 06/24/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049102 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,351.00 | 06/24/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049104 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,406.10 | 06/19/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049100 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,154.35 | 06/12/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049098 |
| Principal investigator 1 | ABBVIE INC. | $11,909.78 | 06/11/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202490977 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,950.70 | 06/05/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049096 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,950.70 | 05/28/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049092 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $97,500.00 | 05/28/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049094 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,465.00 | 05/22/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049086 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $20,494.35 | 05/22/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049088 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,351.00 | 05/22/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049090 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $277,500.00 | 05/16/2025 | Non-covered Recipient Entity Cenexel Cns - Torrance | An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants with DSM-5 Schizophrenia | No dispute reported | 06/30/2026 | 1235998290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,500.00 | 05/14/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737232 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 04/28/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder | No dispute reported | 06/30/2026 | 1202479795 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,557.75 | 04/28/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049243 |
| Principal investigator 1 | ABBVIE INC. | $29,318.90 | 04/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202478178 |
| Principal investigator 1 | ABBVIE INC. | $3,517.31 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202474526 |
| Principal investigator 1 | ABBVIE INC. | $22,111.67 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202474531 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339343 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339345 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339347 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339349 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339351 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339353 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,834.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339355 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,597.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339391 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $108.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339393 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339395 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339397 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339399 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339401 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339403 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339442 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339444 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339446 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,834.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339448 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,597.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339450 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339452 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,597.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339814 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242339816 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $78,662.85 | 03/26/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $264.55 | 03/24/2025 | Non-covered Recipient Entity Cenexel CNS-Torrance | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220737404 |
| Principal investigator 1 | ABBVIE INC. | $39,828.05 | 03/19/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202464847 |
| Principal investigator 1 | ABBVIE INC. | $24,495.11 | 03/19/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202464852 |
| Principal investigator 1 | ABBVIE INC. | $28,687.05 | 03/19/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202464864 |
| Principal investigator 1 | ABBVIE INC. | $30,996.50 | 03/19/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202464868 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $22,484.80 | 03/19/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. | No dispute reported | 06/30/2026 | 1176630561 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $540.80 | 03/19/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. | No dispute reported | 06/30/2026 | 1176630593 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,351.00 | 03/19/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049239 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334810 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334812 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334814 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334848 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334850 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334852 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334854 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334856 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334890 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334892 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334894 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334896 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,412.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334898 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334950 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,036.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334952 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334954 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334956 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242334958 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335010 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,874.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335012 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335014 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335016 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335018 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335020 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335022 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335078 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,303.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335080 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335082 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335084 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335086 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335088 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335090 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335130 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335132 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,834.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335134 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335136 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $101.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335138 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,412.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335140 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335142 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,036.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335194 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335196 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335198 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335200 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335202 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,874.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335204 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335206 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335240 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335242 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335244 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335246 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335248 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,303.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335250 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $101.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335252 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335402 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,412.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335404 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335406 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,036.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335408 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335410 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335412 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335444 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335446 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,874.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335448 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335450 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335452 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335454 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335456 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335474 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335476 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335478 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335480 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335482 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335484 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335486 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,303.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335488 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335490 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335528 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335530 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335532 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335534 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $101.00 | 03/10/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242335536 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,556.30 | 03/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049235 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,351.00 | 03/04/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049237 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $28,498.00 | 03/03/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. | No dispute reported | 06/30/2026 | 1176629985 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $11,767.65 | 02/25/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049233 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,131.40 | 02/20/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049261 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,135.22 | 02/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049223 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $122.50 | 02/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049225 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $977.32 | 02/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049227 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,500.53 | 02/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049229 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,650.16 | 02/18/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049231 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $25.48 | 02/11/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049209 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,722.90 | 02/11/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049221 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332094 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332196 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332198 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332200 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332202 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332204 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332206 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332210 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332296 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332298 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332300 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332302 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332304 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,834.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332306 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 02/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | ITI-007-452 | No dispute reported | 06/30/2026 | 1242332308 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $124,567.94 | 01/30/2025 | Non-covered Recipient Entity Collaborative Neuroscience Network | An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia | No dispute reported | 06/30/2026 | 1235997944 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,083.20 | 01/29/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049219 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $750.00 | 01/28/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. | No dispute reported | 06/30/2026 | 1176624743 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,000.00 | 01/28/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. | No dispute reported | 06/30/2026 | 1176624751 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,506.00 | 01/28/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. | No dispute reported | 06/30/2026 | 1176624764 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,544.45 | 01/21/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049217 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,235.30 | 01/17/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049215 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $102,867.18 | 01/15/2025 | Non-covered Recipient Entity Collaborative Neuroscience Network | An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | No dispute reported | 06/30/2026 | 1235997940 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,538.05 | 01/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049211 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,057.80 | 01/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia | No dispute reported | 06/30/2026 | 1244049213 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $17,494.58 | 01/07/2025 | Non-covered Recipient Entity COLLABORATIVE NEUROSCIENCE RESEARCH LLC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049259 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $352,857.80 | 01/06/2025 | Non-covered Recipient Entity Collaborative Neuroscience Network | A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) | No dispute reported | 06/30/2026 | 1235997942 |